Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A Next-Generation Sequencing Study in a Cohort of Patients with Parkinson’s Disease

ABSTRACT: A Next-Generation Sequencing Study in a Cohort of Patients with Parkinson’s Disease

PROVIDER: PRJEB68303 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other
	ERR12246700_1.fastq.gz	Fastqsanger.gz
	ERR12246700_2.fastq.gz	Fastqsanger.gz
	ERR12246701_1.fastq.gz	Fastqsanger.gz
	ERR12246701_2.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 239

Similar Datasets

A Next-Generation Sequencing Study in a Cohort of Patients with Parkinson’s Disease

Project description:Background: Parkinson’s disease (PD) is a multisystem and multifactorial disorder. Therefore, the application of modern genetic techniques may assist in unraveling its complex pathophysiology. Methods: We conducted a clinical-demographic evaluation of 126 patients with PD, all of whom were Caucasian and of Sicilian ancestry. DNA was extracted from peripheral blood for each patient, followed by sequencing using a Next-Generation Sequencing system. This system was based on a custom gene panel comprising 162 genes. The sample underwent further filtering, taking into account allele frequencies of genetic variants, their presence in the Human Gene Mutation Database, and their association in the literature with PD or other movement/neurodegenerative disorders. Results: The largest number of variants was identified in the leucine-rich repeat kinase 2 (LRRK2) gene. However, variants in other genes, such as acid beta-glucosidase (GBA), DNA polymerase gamma, catalytic subunit (POLG), and parkin RBR E3 ubiquitin protein ligase (PRKN), were also discovered. Interestingly, some of these variants had not been previously associated with PD. Conclusions: Enhancing our understanding of the genetic basis of PD and identifying new variants possibly linked to the disease will contribute to improved diagnostic accuracy, therapeutic developments, and prognostic insights for affected individuals.

2024-10-14 | E-MTAB-13523 | biostudies-arrayexpress

A transcriptome analysis study on mRNA and long non-coding RNAs in patients with Parkinson’s disease

Project description:Parkinson’s disease (PD) is the second most common neurodegenerative disorder, affecting ~2–3% of people over 65 years of age. Recent studies have revealed that the molecular pathogenesis of PD involves a series of pathways and neurobiological processes, such as protein degradation, mitochondrial dysfunction, oxidative stress, autophagy, calcium homeostasis, axonal transport, and neuroinflammation, all suggesting that both the onset and course of PD is a complex multilevel and systematic process. Accumulating evidence demonstrates that long non-coding RNAs (lncRNAs) affect the pathogenesis of several diseases, such as cancers, immunological diseases, and neurodegenerative disorders, including Alzheimer’s disease and PD. Next generation sequencing provides a high-throughput method for exploring the diverse polyadenylated RNA populations. This approach allows accurate identification and quantitation of mRNAs and other non-coding RNAs, such as lncRNAs. The present study explored mRNAs and lncRNAs expression by using the next generation sequencing analysis (NGS) and the quantitative real-time PCR (qRT-PCR) assay for the confirmation of the NGS results, followed by functional analysis of the results.

2023-01-16 | E-MTAB-11326 | biostudies-arrayexpress

Hsa-miR-144-3p is down-regulated in serum from drug-naïve and advanced Parkinson’s disease patients.

Project description:Advanced age represents one of the major risk factors for Parkinson’s Disease. Recent studies posit a role for microRNAs in Parkinson’s Disease and it is well established that microRNAs are remodelled during ageing, but the relationship between the two processes have not been clarified yet. The aim of the present study is to unravel the relevance of microRNAs as biomarkers of Parkinson’s Disease within the ageing framework. We used Next Generation Sequencing to profile serum microRNAs from samples informative for Parkinson’s Disease (recently diagnosed, drug-naïve Parkinson’s Disease patients) and healthy ageing (centenarians) plus healthy controls age-matched with Parkinson’s Disease patients. Potential candidates, emerging from the combination of differential expression and network analyses, were further validated in an independent cohort including both drug-naïve and advanced Parkinson’s Disease patients together with healthy siblings of Parkinson’s Disease patients at higher genetic risk for Parkinson’s Disease. While we did not find evidences of microRNAs co-regulated in Parkinson’s Disease and ageing, we report that hsa-miR-144-3p is consistently down-regulated in early and advanced Parkinson’s Disease and in Parkinson’s Disease siblings. Interestingly, functional analysis revealed that hsa-miR-144-3p is involved in the regulation of coagulation, a process known to be altered in Parkinson’s Disease. Our results consistently show the down-regulation of hsa-mir144-3p in early and advanced Parkinson’s Disease, robustly confirmed across a variety of analytical and experimental analyses. These results are promising, and additional research is needed to unveil the functional details of its relevance and involvement in Parkinson’s Disease.

2022-02-02 | GSE180193 | GEO

Targeted next generation sequencing of cfDNA from lung cancer patients enrolled in the GALAXY-1 trial (NCT01348126)

Project description:We evaluated whether targeted next-generation sequencing (NGS) using the Ion Torrent Personal Genome Sequencer of cfDNA could identify prognostic or predictive factors for overall survival (OS) or progression free survival (PFS) within a large cohort of patients with advanced lung adenocarcinoma enrolled in the GALAXY-1 trial.

2018-01-10 | E-MTAB-5749 | biostudies-arrayexpress

Next-generation sequencing of cancers of unknown primary (Affymetrix GenomeWideSNP data)

Project description:SNP 6.0 copy number analysis was done to validate results from next-generation sequencing read-depth CNV analysis in a cohort of cancers of unknown primary Affymetrix SNP arrays were performed according to the manufacturer's directions on DNA extracted from cryopreserved tissue samples 7 samples

2013-08-07 | E-GEOD-49602 | biostudies-arrayexpress

Next generation sequence analysis

Project description:Next generation sequence analysis

| PRJNA560769 | ENA

Next-generation sequencing of cancers of unknown primary (Affymetrix GenomeWideSNP data)

Project description:SNP 6.0 copy number analysis was done to validate results from next-generation sequencing read-depth CNV analysis in a cohort of cancers of unknown primary

2013-08-07 | GSE49602 | GEO

Role and dysregulation of miRNA in patients with Parkinson’s disease

Project description:Parkinson’s disease (PD) is the most common movement disorder in the aging population, with an estimated prevalence of 1% of people above 60 years old. More recently, PD risk genes, have been found to be regulated by the small non-coding RNAs, (microRNAs or miRNAs), and, as such, may contribute to PD development through a direct regulation on the mitochondrial and immune pathways. Many of these are influenced by epigenetic mechanisms, among which ones mediated by, miRNAs, that regulate gene expression at a post transcriptional level by binding to their 3′ un-translated region (3′ UTR) of target messenger RNAs (mRNAs) inducing mRNA degradation and translational repression. This study aimed to identify and characterize miRNA to evaluate their possible deregulation in PD patients compared to CRTL. In addition, we investigated how specific miRNAs are able to target genes and, thus, to modulate their functions in PD patient. Small RNA expression profiling was performed by next-generation sequencing in PD patients and CTRL after filtered out low-quality reads and trimming the adaptors. The obtained high-quality reads were aligned against the human genome reference.

2023-09-01 | E-MTAB-12087 | biostudies-arrayexpress

Next Generation Sequencing to Study FLK-affected genes

Project description:Next Generation Sequencing to Study FLK-affected genes

| PRJNA690591 | ENA

Next Generation Sequencing to Study LUX-affected genes.

Project description:Next Generation Sequencing to Study LUX-affected genes.

| PRJNA475754 | ENA